Producers Resource Center

Intensive Rectal Cancer Treatment Shows Promise

The study included individuals with poor-risk rectal cancer.  That means they have a high likelihood of disease recurrence and poor survival odds despite receiving standard chemotherapy and optimum surgery.

Patients underwent 12 weeks of chemotherapy treatment with capecitabine and oxaliplatin, followed by chemoradiotherapy with capecitabine and surgery, followed by another 12 weeks of capecitabine treatment. 

After 36 months, 68 percent of the patients had no cancer progression, and the overall survival rate was 83 percent. After five years, the overall survival rate was 75 percent. 

Tumor downstaging was shown in most patients receiving neoadjuvant treatment with a low incidence of involved [circumferential resection margins (CRMs)] in the surgical specimens.  Before treatment, 90 percent of eligible patients had tumors with CRMs at risk or involved. 

The study was published online Jan. 25 in The Lancet Oncology.

Posted by the American Association for Critical Illness Insurance which tracks information regarding the three primary critical illnesses which impact Americans, cancer, heart attack and stroke.

Share and Enjoy:
  • Print this article!
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • Reddit
  • Slashdot
  • StumbleUpon
  • Twitter
  • LinkedIn

Tags: , , , , , , ,